The EU AI Act, Regulation (EU) 2024/1689, is the European Union's horizontal law on artificial intelligence. It takes a risk-based approach, banning a small set of unacceptable practices, imposing detailed obligations on high-risk systems, and setting transparency rules for limited-risk systems. Healthcare is heavily affected because AI systems that are medical devices, or safety components of medical devices, requiring notified body assessment under the MDR or IVDR are generally classified as high risk. Such systems must meet requirements on risk management, data governance, technical documentation, transparency, human oversight, and accuracy and robustness. The AI Act applies alongside the MDR and IVDR rather than replacing them, so manufacturers of AI-enabled medical devices must satisfy both regimes. Its obligations phase in over a multi-year timeline following entry into force in 2024.
What is the EU AI Act in healthcare?
The EU AI Act, Regulation (EU) 2024/1689, is the EU's risk-based law on artificial intelligence; many medical AI systems are classified as high risk.
Are medical AI devices high risk under the AI Act?
Generally yes. AI systems that are medical devices or their safety components and require notified body assessment under the MDR or IVDR are classified as high-risk under the AI Act.
Does the AI Act replace the MDR?
No. The AI Act applies in addition to the MDR and IVDR. Manufacturers of AI-enabled medical devices must comply with both frameworks.
Dėl vaistinių preparatų tiekimo sutrikimo
Informuojame, kad laikinai sutriko šių vaistinių preparatų tiekimas Lietuvos Respublikos rinkai. NPAKID7 Vaistinio preparato pavadinimas Veiklioji medžiaga Stiprumas Farmacinė forma Kiekis pakuotėje Registruoto...
Lithuania VVKTNewΑνάκληση της παρτίδας 202412 του Καλλυντικού προϊόντος ALOHA Nails & Cosmetics REPAIR GEL MILKY LILAC, λόγω παρουσίας TPO
Αρ. πρωτ. 92834 Ανάκληση της παρτίδας 202412 του Καλλυντικού προϊόντος ALOHA Nails & Cosmetics REPAIR GEL MILKY LILAC, λόγω παρουσίας
Greece EOFDėl vaistinių preparatų tiekimo sutrikimo
Informuojame, kad laikinai sutriko šių vaistinių preparatų tiekimas Lietuvos Respublikos rinkai. NPAKID7 Vaistinio preparato pavadinimas Veiklioji medžiaga Stiprumas Farmacinė forma Kiekis pakuotėje Registruoto...
Lithuania VVKTWinrevair (sotatercept) | Relatório de avaliação de financiamento público disponível | Deferimento
Data : 13/07/2026
Portugal INFARMEDMedicamentos e calor: Cuidados essenciais para garantir a sua segurança e eficácia
Data : 18/07/2026
Portugal INFARMEDAz NNGYK indikáción túli gyógyszerrendelési ajánlást adott ki a tranexamic acid hatóanyagú gyógyszerekre
Az NNGYK indikáción túli gyógyszerrendelési ajánlásai link: tranexamic acid hatóanyagú gyógyszerek lokális és intraarticularis alkalmazásának intézményi szintű engedélyezése vérzéscsökkentés céljából or
Hungary NNGYKWest Nil Virus (WNV) – FrankreichNeu
West Nil Virus (WNV) – Frankreich Neu Sicherheitsinformation | Blut & Gewebe | 17.07.2026 Dem Bundesamt für Sicherheit im Gesundheitswesen (BASG) wurde von der französischen Behörde mitgete...
Austria BASG